Oncolys BioPharma Inc.
4588・Growth Market・Pharmaceuticals
Governance
The company has a Board of Directors and a Board of Corporate Auditors (5 directors in total, including 2 outside directors). No Nomination Committee or Compensation Committee has been established; the Board of Corporate Auditors (comprising 1 full-time auditor and 2 outside auditors) performs the oversight function. The outside director ratio is 40% (2 of 5 directors).
Risk Management
The Company appoints a Risk Management Officer (one director) in accordance with the
Shareholder Returns
Annual dividend for FY2025 (ending December 2025) is no dividend (¥0). No dividend is planned for FY2026 (ending December 2026) either. As a research and development-oriented venture company, the company continues to prioritize strengthening internal reserves and maintains no dividend.
Dividend Policy
The annual dividend for FY2025 (ending December 2025) is ¥0 (¥0 at end of second quarter, ¥0 at year-end). The forecast for FY2026 (ending December 2026) is also ¥0 for the year (¥0 at end of second quarter, ¥0 at year-end). Full-year earnings forecasts are not disclosed because it is difficult to make a reasonable estimate. As a research and development-oriented venture company incurring upfront investment-type business expenditures, the company's policy is to determine its dividend policy while taking into account the strengthening of its management foundation and the enhancement of internal reserves.
ESG
The company has not established a dedicated sustainability organization, but addresses relevant matters within its internal control and risk management framework. On the human capital side, it has implemented a flextime system, a selectable work-start-time system, and restricted stock compensation, among other measures, to promote the securing of diverse talent. Quantitative ESG indicators and targets have not yet been established, and the company is currently considering whether such targets should be set going forward.
Last updated: March 25, 2026